Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer
There is mounting evidence that the immune system can spontaneously clear malignant lesions before they manifest as overt cancer, albeit this activity has been difficult to demonstrate in humans. The calreticulin ( CALR ) exon 9 mutations are driver mutations in patients with chronic myeloproliferat...
Gespeichert in:
Veröffentlicht in: | Cancer Immunology, Immunotherapy Immunotherapy, 2020-02, Vol.69 (2), p.315-324 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 324 |
---|---|
container_issue | 2 |
container_start_page | 315 |
container_title | Cancer Immunology, Immunotherapy |
container_volume | 69 |
creator | Holmström, Morten Orebo Cordua, Sabrina Skov, Vibe Kjær, Lasse Pallisgaard, Niels Ellervik, Christina Hasselbalch, Hans Carl Andersen, Mads Hald |
description | There is mounting evidence that the immune system can spontaneously clear malignant lesions before they manifest as overt cancer, albeit this activity has been difficult to demonstrate in humans. The calreticulin (
CALR
) exon 9 mutations are driver mutations in patients with chronic myeloproliferative neoplasms (MPN), which are chronic blood cancers. The
CALR
mutations generate a neo-antigen that is recognized by patient T cells, and T cells isolated from a patient with a
CALR
-mutation can recognize and kill autologous
CALR
-mutant cells. Surprisingly, healthy individuals display frequent and strong T cell responses to the CALR neo-antigens too. Furthermore, healthy individuals display immune responses to all parts of the mutant CALR epitope, and the CALR neo-epitope specific responses are memory T cell responses. These data suggest that although healthy individuals might acquire a
CALR
mutation, the mutant cells can be eliminated by the immune system. Additionally, a small fraction of healthy individuals harbor a
CALR
exon 9 mutation. Four healthy individuals carrying
CALR
mutations underwent a full medical examination including a bone marrow biopsy after a median follow up of 6.2 years. None of these patients displayed any signs of
CALR
-mutant MPN. Additionally, all healthy individuals displayed strong CALR neo-epitope specific T cell responses suggesting that these healthy individuals retained their
CALR
-mutant cells in the editing stage for several years. Thus, we suggest that
CALR
-mutant MPN could be a disease model of cancer immuno-editing, as we have demonstrated that
CALR
-mutant MPN displays all three stages described in the theory of cancer immuno-editing. |
doi_str_mv | 10.1007/s00262-019-02473-y |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11027882</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2350714085</sourcerecordid><originalsourceid>FETCH-LOGICAL-c431t-793964db8d311b2dac2b4339832832a6408889bcda31e7fb0e90d2a3abbe76fd3</originalsourceid><addsrcrecordid>eNp9kU9rGzEQxUVJaZy0XyCHIMi1247-rFc6hWDSJGDopT0LraS1FXYlR1o7-NtH7bpOcikIRsz85s2Dh9AFgW8EoPmeAeicVkBkBZQ3rNp_QDPCWWmJmpygGTAOVQPAT9FZzo_lQ0HKT-iUEUlqUfMZ6m533rpgHI4d9sOwDQ673g8-6NHH8HXqxcpZP_qwwjrYI5aN3jjsA94U1oUx42c_rvHaDXqMfVx5o3tsdBFPn9HHTvfZfTnUc_T7x-2vxX21_Hn3sLhZVoYzMlaNZHLObSssI6SlVhvacsakYLQ8PecghJCtsZoR13QtOAmWaqbb1jXzzrJzdD3pbrbt4KwprpLu1Sb5Qae9itqr95Pg12oVd4oQoI0QtChcHRRSfNq6PKrHuE2hmFaU1dCQ4qEuFJ0ok2LOyXXHEwTUn3DUFI4q4ai_4ah9Wbp8a-648i-NArAJyGUUVi693v6P7AtOfZ06</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2350714085</pqid></control><display><type>article</type><title>Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer</title><source>MEDLINE</source><source>SpringerNature Complete Journals</source><source>PubMed Central</source><creator>Holmström, Morten Orebo ; Cordua, Sabrina ; Skov, Vibe ; Kjær, Lasse ; Pallisgaard, Niels ; Ellervik, Christina ; Hasselbalch, Hans Carl ; Andersen, Mads Hald</creator><creatorcontrib>Holmström, Morten Orebo ; Cordua, Sabrina ; Skov, Vibe ; Kjær, Lasse ; Pallisgaard, Niels ; Ellervik, Christina ; Hasselbalch, Hans Carl ; Andersen, Mads Hald</creatorcontrib><description>There is mounting evidence that the immune system can spontaneously clear malignant lesions before they manifest as overt cancer, albeit this activity has been difficult to demonstrate in humans. The calreticulin (
CALR
) exon 9 mutations are driver mutations in patients with chronic myeloproliferative neoplasms (MPN), which are chronic blood cancers. The
CALR
mutations generate a neo-antigen that is recognized by patient T cells, and T cells isolated from a patient with a
CALR
-mutation can recognize and kill autologous
CALR
-mutant cells. Surprisingly, healthy individuals display frequent and strong T cell responses to the CALR neo-antigens too. Furthermore, healthy individuals display immune responses to all parts of the mutant CALR epitope, and the CALR neo-epitope specific responses are memory T cell responses. These data suggest that although healthy individuals might acquire a
CALR
mutation, the mutant cells can be eliminated by the immune system. Additionally, a small fraction of healthy individuals harbor a
CALR
exon 9 mutation. Four healthy individuals carrying
CALR
mutations underwent a full medical examination including a bone marrow biopsy after a median follow up of 6.2 years. None of these patients displayed any signs of
CALR
-mutant MPN. Additionally, all healthy individuals displayed strong CALR neo-epitope specific T cell responses suggesting that these healthy individuals retained their
CALR
-mutant cells in the editing stage for several years. Thus, we suggest that
CALR
-mutant MPN could be a disease model of cancer immuno-editing, as we have demonstrated that
CALR
-mutant MPN displays all three stages described in the theory of cancer immuno-editing.</description><identifier>ISSN: 0340-7004</identifier><identifier>EISSN: 1432-0851</identifier><identifier>DOI: 10.1007/s00262-019-02473-y</identifier><identifier>PMID: 31915854</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Animals ; Antigens ; Antigens, Neoplasm - immunology ; Autografts ; Biomarkers, Tumor ; Biopsy ; Blood cancer ; Bone marrow ; Calreticulin ; Calreticulin - genetics ; Calreticulin - metabolism ; Cancer ; Cancer Research ; Cell Transformation, Neoplastic ; Disease Models, Animal ; Disease Susceptibility ; Editing ; Epitopes ; Epitopes - immunology ; Focussed Research Review ; Hematologic Neoplasms - etiology ; Hematologic Neoplasms - metabolism ; Humans ; Immune evasion ; Immune system ; Immunological memory ; Immunology ; Immunomodulation - genetics ; Lymphocytes ; Lymphocytes T ; Medicine ; Medicine & Public Health ; Memory cells ; Mutants ; Mutation ; Oncology ; Patients ; Tumor Escape - genetics</subject><ispartof>Cancer Immunology, Immunotherapy, 2020-02, Vol.69 (2), p.315-324</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020</rights><rights>Cancer Immunology, Immunotherapy is a copyright of Springer, (2020). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c431t-793964db8d311b2dac2b4339832832a6408889bcda31e7fb0e90d2a3abbe76fd3</citedby><cites>FETCH-LOGICAL-c431t-793964db8d311b2dac2b4339832832a6408889bcda31e7fb0e90d2a3abbe76fd3</cites><orcidid>0000-0002-3764-8578</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11027882/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11027882/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,41467,42536,51297,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31915854$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Holmström, Morten Orebo</creatorcontrib><creatorcontrib>Cordua, Sabrina</creatorcontrib><creatorcontrib>Skov, Vibe</creatorcontrib><creatorcontrib>Kjær, Lasse</creatorcontrib><creatorcontrib>Pallisgaard, Niels</creatorcontrib><creatorcontrib>Ellervik, Christina</creatorcontrib><creatorcontrib>Hasselbalch, Hans Carl</creatorcontrib><creatorcontrib>Andersen, Mads Hald</creatorcontrib><title>Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer</title><title>Cancer Immunology, Immunotherapy</title><addtitle>Cancer Immunol Immunother</addtitle><addtitle>Cancer Immunol Immunother</addtitle><description>There is mounting evidence that the immune system can spontaneously clear malignant lesions before they manifest as overt cancer, albeit this activity has been difficult to demonstrate in humans. The calreticulin (
CALR
) exon 9 mutations are driver mutations in patients with chronic myeloproliferative neoplasms (MPN), which are chronic blood cancers. The
CALR
mutations generate a neo-antigen that is recognized by patient T cells, and T cells isolated from a patient with a
CALR
-mutation can recognize and kill autologous
CALR
-mutant cells. Surprisingly, healthy individuals display frequent and strong T cell responses to the CALR neo-antigens too. Furthermore, healthy individuals display immune responses to all parts of the mutant CALR epitope, and the CALR neo-epitope specific responses are memory T cell responses. These data suggest that although healthy individuals might acquire a
CALR
mutation, the mutant cells can be eliminated by the immune system. Additionally, a small fraction of healthy individuals harbor a
CALR
exon 9 mutation. Four healthy individuals carrying
CALR
mutations underwent a full medical examination including a bone marrow biopsy after a median follow up of 6.2 years. None of these patients displayed any signs of
CALR
-mutant MPN. Additionally, all healthy individuals displayed strong CALR neo-epitope specific T cell responses suggesting that these healthy individuals retained their
CALR
-mutant cells in the editing stage for several years. Thus, we suggest that
CALR
-mutant MPN could be a disease model of cancer immuno-editing, as we have demonstrated that
CALR
-mutant MPN displays all three stages described in the theory of cancer immuno-editing.</description><subject>Animals</subject><subject>Antigens</subject><subject>Antigens, Neoplasm - immunology</subject><subject>Autografts</subject><subject>Biomarkers, Tumor</subject><subject>Biopsy</subject><subject>Blood cancer</subject><subject>Bone marrow</subject><subject>Calreticulin</subject><subject>Calreticulin - genetics</subject><subject>Calreticulin - metabolism</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Cell Transformation, Neoplastic</subject><subject>Disease Models, Animal</subject><subject>Disease Susceptibility</subject><subject>Editing</subject><subject>Epitopes</subject><subject>Epitopes - immunology</subject><subject>Focussed Research Review</subject><subject>Hematologic Neoplasms - etiology</subject><subject>Hematologic Neoplasms - metabolism</subject><subject>Humans</subject><subject>Immune evasion</subject><subject>Immune system</subject><subject>Immunological memory</subject><subject>Immunology</subject><subject>Immunomodulation - genetics</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Memory cells</subject><subject>Mutants</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Patients</subject><subject>Tumor Escape - genetics</subject><issn>0340-7004</issn><issn>1432-0851</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kU9rGzEQxUVJaZy0XyCHIMi1247-rFc6hWDSJGDopT0LraS1FXYlR1o7-NtH7bpOcikIRsz85s2Dh9AFgW8EoPmeAeicVkBkBZQ3rNp_QDPCWWmJmpygGTAOVQPAT9FZzo_lQ0HKT-iUEUlqUfMZ6m533rpgHI4d9sOwDQ673g8-6NHH8HXqxcpZP_qwwjrYI5aN3jjsA94U1oUx42c_rvHaDXqMfVx5o3tsdBFPn9HHTvfZfTnUc_T7x-2vxX21_Hn3sLhZVoYzMlaNZHLObSssI6SlVhvacsakYLQ8PecghJCtsZoR13QtOAmWaqbb1jXzzrJzdD3pbrbt4KwprpLu1Sb5Qae9itqr95Pg12oVd4oQoI0QtChcHRRSfNq6PKrHuE2hmFaU1dCQ4qEuFJ0ok2LOyXXHEwTUn3DUFI4q4ai_4ah9Wbp8a-648i-NArAJyGUUVi693v6P7AtOfZ06</recordid><startdate>20200201</startdate><enddate>20200201</enddate><creator>Holmström, Morten Orebo</creator><creator>Cordua, Sabrina</creator><creator>Skov, Vibe</creator><creator>Kjær, Lasse</creator><creator>Pallisgaard, Niels</creator><creator>Ellervik, Christina</creator><creator>Hasselbalch, Hans Carl</creator><creator>Andersen, Mads Hald</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3764-8578</orcidid></search><sort><creationdate>20200201</creationdate><title>Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer</title><author>Holmström, Morten Orebo ; Cordua, Sabrina ; Skov, Vibe ; Kjær, Lasse ; Pallisgaard, Niels ; Ellervik, Christina ; Hasselbalch, Hans Carl ; Andersen, Mads Hald</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c431t-793964db8d311b2dac2b4339832832a6408889bcda31e7fb0e90d2a3abbe76fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Antigens</topic><topic>Antigens, Neoplasm - immunology</topic><topic>Autografts</topic><topic>Biomarkers, Tumor</topic><topic>Biopsy</topic><topic>Blood cancer</topic><topic>Bone marrow</topic><topic>Calreticulin</topic><topic>Calreticulin - genetics</topic><topic>Calreticulin - metabolism</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Cell Transformation, Neoplastic</topic><topic>Disease Models, Animal</topic><topic>Disease Susceptibility</topic><topic>Editing</topic><topic>Epitopes</topic><topic>Epitopes - immunology</topic><topic>Focussed Research Review</topic><topic>Hematologic Neoplasms - etiology</topic><topic>Hematologic Neoplasms - metabolism</topic><topic>Humans</topic><topic>Immune evasion</topic><topic>Immune system</topic><topic>Immunological memory</topic><topic>Immunology</topic><topic>Immunomodulation - genetics</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Memory cells</topic><topic>Mutants</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Patients</topic><topic>Tumor Escape - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Holmström, Morten Orebo</creatorcontrib><creatorcontrib>Cordua, Sabrina</creatorcontrib><creatorcontrib>Skov, Vibe</creatorcontrib><creatorcontrib>Kjær, Lasse</creatorcontrib><creatorcontrib>Pallisgaard, Niels</creatorcontrib><creatorcontrib>Ellervik, Christina</creatorcontrib><creatorcontrib>Hasselbalch, Hans Carl</creatorcontrib><creatorcontrib>Andersen, Mads Hald</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer Immunology, Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Holmström, Morten Orebo</au><au>Cordua, Sabrina</au><au>Skov, Vibe</au><au>Kjær, Lasse</au><au>Pallisgaard, Niels</au><au>Ellervik, Christina</au><au>Hasselbalch, Hans Carl</au><au>Andersen, Mads Hald</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer</atitle><jtitle>Cancer Immunology, Immunotherapy</jtitle><stitle>Cancer Immunol Immunother</stitle><addtitle>Cancer Immunol Immunother</addtitle><date>2020-02-01</date><risdate>2020</risdate><volume>69</volume><issue>2</issue><spage>315</spage><epage>324</epage><pages>315-324</pages><issn>0340-7004</issn><eissn>1432-0851</eissn><abstract>There is mounting evidence that the immune system can spontaneously clear malignant lesions before they manifest as overt cancer, albeit this activity has been difficult to demonstrate in humans. The calreticulin (
CALR
) exon 9 mutations are driver mutations in patients with chronic myeloproliferative neoplasms (MPN), which are chronic blood cancers. The
CALR
mutations generate a neo-antigen that is recognized by patient T cells, and T cells isolated from a patient with a
CALR
-mutation can recognize and kill autologous
CALR
-mutant cells. Surprisingly, healthy individuals display frequent and strong T cell responses to the CALR neo-antigens too. Furthermore, healthy individuals display immune responses to all parts of the mutant CALR epitope, and the CALR neo-epitope specific responses are memory T cell responses. These data suggest that although healthy individuals might acquire a
CALR
mutation, the mutant cells can be eliminated by the immune system. Additionally, a small fraction of healthy individuals harbor a
CALR
exon 9 mutation. Four healthy individuals carrying
CALR
mutations underwent a full medical examination including a bone marrow biopsy after a median follow up of 6.2 years. None of these patients displayed any signs of
CALR
-mutant MPN. Additionally, all healthy individuals displayed strong CALR neo-epitope specific T cell responses suggesting that these healthy individuals retained their
CALR
-mutant cells in the editing stage for several years. Thus, we suggest that
CALR
-mutant MPN could be a disease model of cancer immuno-editing, as we have demonstrated that
CALR
-mutant MPN displays all three stages described in the theory of cancer immuno-editing.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>31915854</pmid><doi>10.1007/s00262-019-02473-y</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-3764-8578</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0340-7004 |
ispartof | Cancer Immunology, Immunotherapy, 2020-02, Vol.69 (2), p.315-324 |
issn | 0340-7004 1432-0851 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11027882 |
source | MEDLINE; SpringerNature Complete Journals; PubMed Central |
subjects | Animals Antigens Antigens, Neoplasm - immunology Autografts Biomarkers, Tumor Biopsy Blood cancer Bone marrow Calreticulin Calreticulin - genetics Calreticulin - metabolism Cancer Cancer Research Cell Transformation, Neoplastic Disease Models, Animal Disease Susceptibility Editing Epitopes Epitopes - immunology Focussed Research Review Hematologic Neoplasms - etiology Hematologic Neoplasms - metabolism Humans Immune evasion Immune system Immunological memory Immunology Immunomodulation - genetics Lymphocytes Lymphocytes T Medicine Medicine & Public Health Memory cells Mutants Mutation Oncology Patients Tumor Escape - genetics |
title | Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T22%3A04%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evidence%20of%20immune%20elimination,%20immuno-editing%20and%20immune%20escape%20in%20patients%20with%20hematological%20cancer&rft.jtitle=Cancer%20Immunology,%20Immunotherapy&rft.au=Holmstr%C3%B6m,%20Morten%20Orebo&rft.date=2020-02-01&rft.volume=69&rft.issue=2&rft.spage=315&rft.epage=324&rft.pages=315-324&rft.issn=0340-7004&rft.eissn=1432-0851&rft_id=info:doi/10.1007/s00262-019-02473-y&rft_dat=%3Cproquest_pubme%3E2350714085%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2350714085&rft_id=info:pmid/31915854&rfr_iscdi=true |